Vontobel Holding Ltd. Purchases New Shares in Takeda Pharmaceutical Co. (NYSE:TAK)

Vontobel Holding Ltd. purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,619 shares of the company's stock, valued at approximately $262,000.

Other large investors have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new stake in shares of Takeda Pharmaceutical during the first quarter worth $37,000. Farther Finance Advisors LLC raised its position in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. bought a new position in Takeda Pharmaceutical in the 4th quarter valued at $52,000. EverSource Wealth Advisors LLC raised its position in shares of Takeda Pharmaceutical by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after acquiring an additional 1,770 shares during the last quarter. Finally, Fifth Third Bancorp lifted its stake in shares of Takeda Pharmaceutical by 85.5% during the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after acquiring an additional 2,411 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.8%

TAK stock traded up $0.12 during mid-day trading on Wednesday, hitting $15.14. 1,629,448 shares of the company were exchanged, compared to its average volume of 1,987,959. The firm has a market cap of $48.17 billion, a P/E ratio of 68.82 and a beta of 0.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $16.00. The firm's 50 day simple moving average is $14.86 and its 200 day simple moving average is $14.35.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. On average, sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.